A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) and Matching Placebo in Dravet Syndrome, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.. Completed at 28 sites in 7 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 3rd registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 16+
University of Colorado, Denver · Sites in United States
Ages 12 mo–24 mo
By country, each count listing its studies:
Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2017.
This study's enrollment of 87 is above the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 25 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
This study is registered under Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
UCB S.A. has 8 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
2 of the studies testing fenfluramine in Epilepsies, Myoclonic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06598449University of Colorado, DenverAssessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age | 2026-12 |
| NCT07112365The University of Texas Health Science Center, HoustonThe FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.
This is a multicenter, 2-cohort trial to first assess the pharmacokinetic and safety profile of a single dose of ZX008 (fenfluramine hydrochloride) oral solution when added to a standard Dravet syndrome treatment regimen containing valproate (VPA) and clobazam (CLB), with or without stiripentol (STP) (Cohort 1), followed by a randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy, safety, and tolerability of ZX008 as adjunctive therapy for seizures in children and young adults with Dravet syndrome (Cohort 2).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZX008 0.5 mg/kg/day (maximum 20 mg/day) dose supplied as an oral solution administered twice a day (BID) in equally divided doses with food.
Drug: ZX008 (Fenfluramine Hydrochloride)
Matching placebo administered twice a day (BID) in equally divided doses with food.
Drug: Matching Placebo
ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. \*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.
Matching Placebo
Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period
Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.
Time frame: 15 weeks (combined Titration + Maintenance Period)
Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period
Percentage of participants who achieved ≥ a 50% reduction in convulsive seizure frequency from Baseline compared to the combined Titration + Maintenance Periods in the ZX008 0.5 mg/kg/day vs placebo groups.
Time frame: 15 weeks (combined Titration + Maintenance Period)
Longest Convulsive Seizure-Free Interval (Days)
Comparison of the duration of the longest convulsive seizure-free interval (days) during the combined Titration + Maintenance Periods for the ZX008 0.5 mg/kg/day and placebo groups.
Time frame: 15 weeks (combined Titration + Maintenance Period)
A total of 28 study sites in Canada, France, Germany, the Netherlands, Spain, the United Kingdom, and the United States enrolled participants for Study 1504 Cohort 2.
| Milestone | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| Started | 43 | 44 |
| Completed | 36 | 41 |
| Not completed | 7 | 3 |
Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.
| Convulsive seizures per 28 days | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period | -3.18 ± 44.121 | -0.65 ± 8.767 |
Percentage of participants who achieved ≥ a 50% reduction in convulsive seizure frequency from Baseline compared to the combined Titration + Maintenance Periods in the ZX008 0.5 mg/kg/day vs placebo groups.
| Percentage of participants | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period | 53.5 | 4.5 |
Comparison of the duration of the longest convulsive seizure-free interval (days) during the combined Titration + Maintenance Periods for the ZX008 0.5 mg/kg/day and placebo groups.
| Days | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| Longest Convulsive Seizure-Free Interval (Days) | 22.0 (3.0 to 105.0) | 13.0 (1.0 to 40.0) |
Collected over The period of observation for Adverse Events extended from the time the subject gave informed consent until the end of the Follow-up Visit (up to Day 120 [Visit 13]).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 2: ZX008 0.5 mg/kg/Day | 0/43 (0%) | 6/43 (14%) | 42/43 (97.7%) |
| Cohort 2: Matching Placebo | 0/44 (0%) | 7/44 (15.9%) | 42/44 (95.5%) |
| Event | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| SeizureNervous system disorders | 1/43 | 4/44 |
| Status epilepticusNervous system disorders | 3/43 | 0/44 |
| OsteochondritisMusculoskeletal and connective tissue disorders | 1/43 | 0/44 |
| LethargyNervous system disorders | 1/43 | 0/44 |
| Abdominal painGastrointestinal disorders | 0/43 | 1/44 |
| PyrexiaGeneral disorders | 0/43 | 1/44 |
| Gastroenteritis viralInfections and infestations | 0/43 | 1/44 |
| Lower respiratory tract infectionInfections and infestations | 0/43 | 1/44 |
| PneumoniaInfections and infestations | 0/43 | 1/44 |
| Generalised tonic-clonic seizureNervous system disorders | 0/43 | 1/44 |
| Event | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 19/43 | 5/44 |
| NasopharyngitisInfections and infestations | 7/43 | 15/44 |
| FatigueGeneral disorders | 11/43 | 2/44 |
| PyrexiaGeneral disorders | 11/43 | 4/44 |
| DiarrheaGastrointestinal disorders | 10/43 | 3/44 |
| SeizureNervous system disorders | 2/43 | 7/44 |
| Blood glucose decreasedInvestigations | 6/43 | 2/44 |
| LethargyNervous system disorders | 6/43 | 2/44 |
| BronchitisInfections and infestations | 5/43 | 2/44 |
| Status epilepticusNervous system disorders | 5/43 | 0/44 |
| Age, Continuous(years) | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo | Total |
|---|---|---|---|
| Cohort 2 | 8.8 ± 4.56 | 9.4 ± 5.05 | 9.1 ± 4.80 |
| Sex: Female, Male(Participants) | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo | Total |
|---|---|---|---|
| Cohort 2 — Female | 20 | 17 | 37 |
| Cohort 2 — Male | 23 | 27 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 10 |
| Not Hispanic or Latino | 25 | 22 | 47 |
| Unknown or Not Reported | 15 | 15 | 30 |
| Race (NIH/OMB)(Participants) | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo | Total |
|---|---|---|---|
| Cohort 2 — American Indian or Alaska Native | 0 | 0 | 0 |
| Cohort 2 — Asian | 2 | 1 | 3 |
| Cohort 2 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Cohort 2 — Black or African American | 1 | 2 | 3 |
| Cohort 2 — White | 23 | 29 | 52 |
| Cohort 2 — More than one race | 0 | 0 | 0 |
| Cohort 2 — Unknown or Not Reported | 17 | 12 | 29 |
| Region of Enrollment(Participants) | Cohort 2: ZX008 0.5 mg/kg/Day | Cohort 2: Matching Placebo | Total |
|---|---|---|---|
| Netherlands | 8 | 2 | 10 |
| France | 13 | 10 | 23 |
| Canada | 4 | 3 | 7 |
| United States | 11 | 11 | 22 |
| Germany | 0 | 3 | 3 |
| Spain | 4 | 6 | 10 |
| United Kingdom | 3 | 9 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Jun 2018, 16 months.
Results were first posted in Oct 2022, 4 years 4 months after primary completion.
Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. →